Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026

Rhea-AI Summary

Smith+Nephew (SNN) will launch ALLEVYN COMPLETE CARE foam dressing and RENASYS EDGE negative pressure wound therapy at EWMA, Bremen, May 6-8, 2026.

ALLEVYN COMPLETE CARE features a five-layer design with ExuLOCK, ExuMASK change indicator and ShearDEFENSE. RENASYS EDGE is a lightweight, modular tNPWT pump reporting improved outcomes and an average 88% therapy-session patient compliance.

AI-generated analysis. Not financial advice.

News Market Reaction – SNN

+1.33%

1 alert

+1.33% News Effect

On the day this news was published, SNN gained 1.33%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patients affected: 14.9m people Healthcare spend share: 4% Bacterial reduction: 100 times fewer bacteria +5 more

8 metrics

Patients affected 14.9m people People in Europe impacted by chronic wounds

Healthcare spend share 4% Share of healthcare spend consumed by chronic wound care in Europe

Bacterial reduction 100 times fewer bacteria Bacteria released vs other foam dressings (in‑vitro tests)

Therapy compliance 88% therapy session compliance Average patient compliance with RENASYS EDGE therapy sessions

Sample size n=9 In‑vitro bacterial performance testing for foam dressings

Statistical significance p<0.01 Superiority in bacterial release dependent on challenge volume

Sample size n=29 Study supporting improved wound outcomes with RENASYS EDGE

Statistical significance p<0.005 Outcome improvement study for RENASYS EDGE

Market Reality Check

Price: $29.95 Vol: Volume 1,452,117 is 1.28x...

normal vol

$29.95 Last Close

Volume Volume 1,452,117 is 1.28x the 20-day average of 1,136,918, indicating elevated trading ahead of the wound-care launch news. normal

Technical Shares at $30.90 are trading below the $34.31 200-day MA and about 20% under the $38.79 52-week high, despite positive product launch messaging.

Peers on Argus

SNN is down 0.83% with mixed moves among key device peers: ZBH is slightly posit...

SNN is down 0.83% with mixed moves among key device peers: ZBH is slightly positive (+0.21%), while PHG, STE, PODD and PEN show modest declines. No peers appeared in the momentum scanner, suggesting a stock-specific reaction rather than a coordinated sector move.

Historical Context

5 past events · Latest: Apr 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 21	Clinical data update	Positive	-4.0%	Five‑year AGILI‑C cartilage repair data showing superior pain relief and function.
Apr 09	Clinical trial results	Positive	+0.3%	REGENETEN trial halving early recovery times with high healing rates vs. standard repair.
Mar 10	Product launch	Positive	-3.0%	Launch of ALLEVYN COMPLETE CARE foam dressing for wound and pressure injury care.
Mar 03	Conference showcase	Positive	+2.8%	AAOS 2026 showcase of CORI robotics, trauma implants and digital planning tools.
Mar 02	Portfolio showcase	Positive	-3.1%	AAOS focus on Tendon Seam Repair System and REGENETEN rotator cuff portfolio.

Pattern Detected

Recent positive clinical and product announcements have sometimes been met with negative price reactions, indicating a tendency toward selling or muted responses on good news.

Recent Company History

Over the last few months, Smith+Nephew has highlighted multiple innovation-driven milestones. In March 2026, it launched ALLEVYN COMPLETE CARE Foam Dressing with performance claims for infection control and pressure injury prevention, yet the stock fell 2.96%. AAOS 2026 showcases in early March around robotics and rotator cuff repair brought mixed price outcomes, including a 2.77% rise and a 3.09% decline. In April 2026, strong 5‑year AGILI‑C implant data and REGENETEN trial results also saw limited or negative moves. Today’s chronic wound-care launch fits this pattern of strong product news against a subdued share price.

Market Pulse Summary

This announcement highlights Smith+Nephew’s continued push into chronic wound management, unveiling ...

Analysis

This announcement highlights Smith+Nephew’s continued push into chronic wound management, unveiling ALLEVYN COMPLETE CARE Foam Dressing and the RENASYS EDGE negative pressure wound therapy system ahead of EWMA 2026. The products target a European wound burden affecting up to 14.9m people and consuming up to 4% of healthcare spend. In recent months, the company has frequently combined clinical data with new product launches, reinforcing an innovation‑led strategy. Investors may watch future updates on adoption, clinical outcomes, and broader portfolio execution as these wound‑care solutions roll out.

Key Terms

negative pressure wound therapy, npwt, meta-analysis

3 terms

negative pressure wound therapy medical

"RENASYS♢ EDGE Negative Pressure Wound Therapy System is designed with simplicity"

Negative pressure wound therapy is a medical treatment that uses a sealed dressing and gentle suction (like a small, controlled vacuum under a bandage) to remove fluid, reduce swelling and promote faster tissue repair in wounds. For investors, it matters because the devices, consumable dressings and clinical adoption drive predictable, recurring revenue and reimbursement decisions; better healing outcomes can expand market share and affect healthcare spending.

npwt medical

"Use of NPWT as part of a Hospital @ Home wound management service."

Negative pressure wound therapy (NPWT) is a medical treatment that uses a sealed dressing and gentle vacuum to remove fluid, reduce swelling and promote tissue growth in open or chronic wounds — think of it like a controlled suction that helps a wound heal from the inside out. Investors care because NPWT involves specialized devices, consumable supplies and reimbursement rules, so changes in clinical adoption, regulatory approvals, or payment policies can directly affect sales, margins and long-term market growth.

meta-analysis technical

"Findings From a Systematic Literature Review and Meta-Analysis."

A meta-analysis combines results from multiple independent studies on the same question to produce a single, more reliable estimate of an effect or outcome. Like averaging many temperature readings to get a truer picture of the weather, it reduces random noise and highlights consistent signals; investors use it to assess how strong and reliable the scientific or economic evidence is, which affects regulatory outlook, product prospects, and valuation risk.

AI-generated analysis. Not financial advice.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026.

Demonstrating a long-term commitment to chronic wound management, Smith+Nephew is launching two new wound care innovations designed to support patient outcomes, simplify wound management and ease the clinical burden. This reflects the scale and urgency of a challenge that affects up to 14.9m people in Europe and consumes up to 4% of healthcare spend¹. Fully supporting clinicians and patients across the continuum of care, these purpose-built products are set to take on the challenge of chronic wounds, drive better clinical outcomes and get patients back to what they love.

ALLEVYN^♢ COMPLETE CARE Foam Dressing has a unique five-layer construction with distinct mode of action capabilities targeted towards both wound management and pressure ulcer prevention. Enhanced ExuLOCK^♢ Technology helps lock in exudate and bacteria^2,3, releasing up to 100 times fewer bacteria than other foam dressings*^4,5. A unique ExuMASK^♢ Change Indicator adds confidence to wound healing by minimising strikethrough and is proven to result in longer wear times than other foam dressings^6,7, while advanced ShearDEFENSE^♢ Unbonded Layer Technology is designed to protect from pressure injuries by dissipating shear forces⁸.

RENASYS^♢  EDGE  Negative Pressure Wound Therapy System is designed with simplicity at its core. Prioritising effectiveness⁹, intuition¹⁰ and patient discretion¹¹, the lightweight pump supports portability and convenience¹², significantly improves wound outcomes**¹³ and results in an average of 88% therapy session patient compliance¹⁴. The modular system’s low-cost maintenance functionality removes annual servicing requirements¹⁵ while the intentional design supports patient self-care.^10,16

At EWMA (Booth E10), Smith+Nephew is proud to drive progress in next-level healing with an integrated range of wound management solutions designed to prevent early and treat powerfully. Combining interactive workshops with expert-led symposiums prepared in partnership with industry specialists, Smith+Nephew’s evolving portfolio continues to reflect a patient-centric approach that supports early intervention and improved outcomes.

Rohit Kashyap, President of Advanced Wound Management at Smith+Nephew said “With chronic wound management a strategic priority, we are excited to launch ALLEVYN COMPLETE CARE Dressing and RENASYS EDGE System at EWMA. Our ongoing commitment to innovation and collaboration continues to drive progress in patient outcomes, as we shape the future of advanced wound care.”

Find us at EWMA in Booth E10, May 6-8 2026.

To learn more about ALLEVYN COMPLETE CARE Foam Dressing, please click here.

To learn more about RENASYS EDGE tNPWT, please click here.

References:
*Tested in-vitro (bacteria within simulated wound exudate), n=9, 3 batches. Superiority met (p <0.01) dependent on challenge volume tested.
** n=29; p<0.005

1. MedTech Europe. White Paper: Shaping the Future of Wound Care in Europe. Published March 31, 2026. Accessed April 20, 2026. https://www.medtecheurope.org/wp-content/uploads/2026/03/mte-wound-care-paper-final_31.03.2026_compressed.pdf

2. Smith+Nephew 2025. Internal report: CSD.AWM.25.019 V2.

3. Smith+Nephew 2025.  Internal report: CSD.AWM.25.008.

4. Smith+Nephew 2025. Internal report: CSD.AWM.25.021 V2.

5. Smith+Nephew 2025. Internal report: CSD.AWM.25.030 V2.

6. Atkinson L, Allen D, Costa B. Poster presented at: European Wound Management Association (EWMA); May 1–3, 2024; London, UK.

7. Milne C, McFee K, Costa B, Askew N, Allen D, Atkinson L. Reduced Clinical and Economic Burden Through Evidence-Based Dressing Selection for Wound Management: Findings From a Systematic Literature Review and Meta-Analysis. Int Wound J. 2026;23 Suppl 1:e70906.

8. Smith+Nephew 2024. Comparison of Frictional Energy Absorber Effectiveness (FEAE) in two five-layer hydrocellular polyurethane foam dressings (HPFD) containing superabsorber and masking layers. CSD.AWM.24.057 V2

9.  Vallejo-Carmona L. Structure guided negative pressure wound therapy (NPWT): personalised tissue biomodulation with an NPWT system in adults and older adults. Journal of Wound Care Vol 34, 2025;11  

10. Smith+Nephew 2022. RENASYS EDGE System Human Factors Summative Report Summary. Internal Report. CSD.AWM.22.071. 

11. Smith+Nephew 2022. How the RENASYS EDGE Negative Pressure Wound Therapy System provides continuity of care to the patient Internal Report. EO.AWM.PCS270.003.V1 

12. Smith+Nephew 2022. Summary of footprint, portability, wearability, weight and audible noise for the RENASYS EDGE system. Internal Report. CSD.AWM.22.067. 

13. Rossato M, Ryrie M, Robinson M, Searle R, Murdoch J. Use of NPWT as part of a Hospital @ Home wound management service. JCN Wound Care. 

14. Smith+Nephew 2025. RENASYS EDGE pump retrospective activity logs analysis, relevant to patient compliance to therapy estimations. Internal Report. CSD.AWM.25.068. 

15. Smith+Nephew 2022. Summary of RENASYS EDGE pump cleaning, self-test and maintenance. Internal Report. CSD.AWM.22.068. 

16. Smith+Nephew 2023. Summary of RENASYS EDGE Pump Alarms and Alerts bench testing. Internal Report. CSD.AWM.23.017. 

Enquiries
Frida Wilhelmsson        +46 (738) 499 429
Smith+Nephew            frida.wilhelmsson@smith-nephew.com

About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

FAQ

When will Smith+Nephew (SNN) unveil ALLEVYN COMPLETE CARE and RENASYS EDGE at EWMA 2026?

They will be presented at EWMA in Bremen on May 6-8, 2026. According to Smith+Nephew, the company will showcase product features, workshops and expert symposiums at Booth E10 during those dates to support clinician and patient education.

What are the key features of ALLEVYN COMPLETE CARE foam dressing from Smith+Nephew (SNN)?

ALLEVYN COMPLETE CARE has a five-layer construction with ExuLOCK, ExuMASK and ShearDEFENSE. According to Smith+Nephew, these elements aim to lock in exudate and bacteria, indicate dressing change and dissipate shear to help prevent pressure injuries.

How does RENASYS EDGE tNPWT claim to support patients and clinicians for SNN?

RENASYS EDGE is a lightweight, modular pump designed for portability and patient self-care. According to Smith+Nephew, it reduces annual servicing needs, prioritises ease of use and reports an average 88% therapy-session patient compliance in internal analyses.

What evidence does Smith+Nephew (SNN) cite for ALLEVYN COMPLETE CARE bacterial reduction claims?

Company materials reference in vitro testing showing ALLEVYN releases up to 100 times fewer bacteria than some foam dressings. According to Smith+Nephew, this result derives from controlled in vitro assays across multiple batches and challenge volumes.

Where can investors and clinicians find Smith+Nephew (SNN) at EWMA 2026 and what will be available?

Smith+Nephew will be at Booth E10 during EWMA, May 6-8, 2026. According to Smith+Nephew, attendees can access interactive workshops, expert-led symposiums and demonstrations of ALLEVYN COMPLETE CARE and RENASYS EDGE products and clinical data.